Log in to search using one of your social media accounts:

 

Tracon commences dosing in Phase III trial of TRC105 to treat angiosarcoma
US-based clinical-stage biopharmaceutical firm Tracon Pharmaceuticals has commenced dosing in its Phase III trial of TRC105 in combination with Votrient (pazopanib) for the treatment of angiosarcoma. (Source: Drug Development Technology)
Source: Drug Development Technology - February 20, 2017 Category: Pharmaceuticals Source Type: news

Propranolol in Angiosarcoma: First Major Advance in Decades Propranolol in Angiosarcoma: First Major Advance in Decades
Promising results in treating advanced angiosarcoma have spawned a collaborative international research effort to assess the effectiveness of adding propranolol to chemotherapy for other cancers.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 31, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Pituitary Lesion of Unknown Origin Pituitary Lesion of Unknown Origin
How was this unusual case of primary epithelioid angiosarcoma accurately diagnosed?Journal of the Endocrine Society (Source: Medscape Pathology Headlines)
Source: Medscape Pathology Headlines - January 23, 2017 Category: Pathology Tags: Diabetes & Endocrinology Journal Article Source Type: news

Poor Prognosis, Chemotherapy Underused for Angiosarcoma in Asian Patients
Angiosarcoma has generally poor survival among Asian patients; though chemotherapy can be effective, it has been underused in the last few decades. (Source: CancerNetwork)
Source: CancerNetwork - January 9, 2017 Category: Cancer & Oncology Authors: Dave Levitan Tags: News Sarcoma Source Type: news

First data on rare sarcomas in Asian patients presented at ESMO Asia in Singapore
(European Society for Medical Oncology) The first data on rare sarcomas in Asian patients is presented in three studies today at the ESMO Asia 2016 Congress in Singapore. Just half of patients with advanced angiosarcoma received chemotherapy even though it improved overall survival. CIC-rearranged sarcomas are shown to have a much worse prognosis than BCOR-rearranged sarcomas and clinical features are identified to aid accurate diagnoses. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - December 16, 2016 Category: Cancer & Oncology Source Type: news

New model to study, find ways to target rare tumor
Angiosarcoma or lymphangiosarcoma, a rare malignant tumor of the blood or lymphatic vessels, has no cure, say cancer researchers. However, through recent study, a team has found a new target that could lead to therapies for this rare type of tumor. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - November 19, 2015 Category: Science Source Type: news

Conventional heart drug stops the progression of cancer
(Texas Tech University Health Sciences Center El Paso) A common heart drug may stop the progression of angiosarcoma, a cancer of the inner lining of blood vessels, according to a study by researchers at Texas Tech University Health Sciences Center El Paso. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 2, 2015 Category: Cancer & Oncology Source Type: news

Skin cancer-causing fusion gene identified
(Kumamoto University) Fusion genes are hybrid genes formed as a result of gene rearrangement or mutation. They can be used to develop more effective treatments for cancers that express their own particular type of fusion gene. Researchers from Kumamoto and Kisato Universities in Japan have revealed a new fusion gene related to cutaneous angiosarcoma, a malignant form of skin cancer with a very poor survival rate. Its discovery will help to improve diagnostic and therapeutic techniques. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2015 Category: Cancer & Oncology Source Type: news

Skin cancer causing fusion gene identified
(Kumamoto University) Fusion genes are hybrid genes formed as a result of gene rearrangement or mutation. They can be used to develop more effective treatments for cancers that express their own particular type of fusion gene. Researchers from Kumamoto and Kisato Universities in Japan have revealed a new fusion gene related to cutaneous angiosarcoma, a malignant form of skin cancer with a very poor survival rate. Its discovery will help to improve diagnostic and therapeutic techniques. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - November 1, 2015 Category: Cancer & Oncology Source Type: news

Mutated gene found in families with multiple tumors, including cardiac angiosarcoma
The mutation found in the POT1 gene causes a rare hereditary syndrome in which patients present multiple tumors, including cardiac angiosarcoma (CAS). It is now possible to identify carriers and intervene early. Currently, familial CAS patients have a poor chance of survival because the tumor is diagnosed when it is in an advanced phase. (Source: ScienceDaily Headlines)
Source: ScienceDaily Headlines - September 25, 2015 Category: Science Source Type: news

A mutated gene found in families with multiple tumors, including cardiac angiosarcoma
(Centro Nacional de Investigaciones Oncologicas (CNIO)) The mutation found in the POT1 gene causes a rare hereditary syndrome in which patients present multiple tumors, including cardiac angiosarcoma (CAS).It is now possible to identify carriers and intervene early. Currently, familial CAS patients have a poor chance of survival because the tumor is diagnosed when it is in an advanced phase.The CNIO's Familial Cancer Consultancy and the Cardiology Unit at the Puerta de Hierro University Hospital have already created a Monitoring Unit to follow-up asymptomatic carriers. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - September 25, 2015 Category: Global & Universal Source Type: news

Great-grandfather who bravely lost half his face to rare cancer is given the devastating news the disease is now incurable
Raymond Martin, 64, from Newcastle, has facial angiosarcoma, a rare form of cancer that has caused a gaping hole to develop under his right eye. Doctors say no treatment can now help him. (Source: the Mail online | Health)
Source: the Mail online | Health - March 24, 2015 Category: Consumer Health News Source Type: news

Adding Bevacizumab Ineffective in AngiosarcomaAdding Bevacizumab Ineffective in Angiosarcoma
Bevacizumab plus weekly paclitaxel did not improve outcomes in advanced angiosarcoma. Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 16, 2014 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

'I've had half my face removed to save my life': Grandfather, 63, is battling rare cancer
Raymond Martin, 63, from Scotswood, Newcastle, has facial angiosarcoma, a cancer of the inner lining of blood vessels. (Source: the Mail online | Health)
Source: the Mail online | Health - December 19, 2013 Category: Consumer Health News Source Type: news

Angiosarcomas: Gaining a Wider Margin of SuccessAngiosarcomas: Gaining a Wider Margin of Success
Dr. Sandra D'Angelo discusses how emerging data are affecting management decisions for patients with angiosarcomas. Medscape Oncology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - October 22, 2013 Category: Consumer Health News Tags: Hematology-Oncology Expert Interview Source Type: news

Angiosarcoma of the Breast
Angiosarcoma of the breast is a rarely diagnosed type of breast cancer. It can grow and spread quickly, and may affect many organs in your body. Learn the symptoms, tests to diagnose, and treatments for angiosarcoma of the breast. (Source: About.com Breast Cancer)
Source: About.com Breast Cancer - August 2, 2013 Category: Cancer & Oncology Authors: breastcancer.guide at about.com Tags: health Source Type: news

Tumor Growth In Breast Cancer And Angiosarcoma Inhibited By Novel Monoclonal Antibody
A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma. In a paper published in the journal Molecular Cancer Therapeutics, a team led by Nancy Klauber-DeMore, MD, professor of surgery and a member of UNC Lineberger Comprehensive Cancer Center, used a monoclonal antibody to target SFRP2 expressed in cells from triple-negative breast cancer and the aggressive blood-vessel malignancy angiosarcoma, reducing the rate of tumor growth... (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - April 23, 2013 Category: Consumer Health News Tags: Breast Cancer Source Type: news

Novel monoclonal antibody inhibits tumor growth in breast cancer and angiosarcoma
(University of North Carolina Health Care) A monoclonal antibody targeting a protein known as SFPR2 has been shown by researchers at the University of North Carolina to inhibit tumor growth in pre-clinical models of breast cancer and angiosarcoma. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 19, 2013 Category: Global & Universal Source Type: news